Recent meetings
No recorded meetings with EU commissioners.
Mission & Goals
VaxThera is an initiative of the private sector, centered in a strong R&D program that is leverage by the academic, scientific and development experience of Professors Jorge Osorio (University of Wisconsin-Madison) and Juan P. Hernandez-Ortiz (Universidad Nacional de Colombia). Its mayor stockholder is Grupo SURA (https://www.gruposura.com/), a well-recognized and established economical group in banking, insurance, risk management, health insurance and health provider systems. Grupo SURA has been working in Colombia and the region for more than 75 years and it has a world-wide reputation as a balanced, profitable, social- oriented corporation. As a dynamic and innovative company, VaxThera operates with specialized expertise, guided by the ethos of saving lives through accessible state-of-the-art biologicals. Our overarching objective is to design and manufacture vaccines and biologicals tailored to address diseases prevalent in low- and middle- income countries.
EU Legislative Interests
Health independence for the LATAM region, local production of vaccines and biologicals, design and R&D of state-of-the-Art vaccines for south-south interactions, pandemic preparedness, Europe-LATAM connections for health and food security.
Communication Activities
VaxThera has strong relations with EU companies in pharma and biotechnology that embraces the capacities and possibilities for the development and manufacturing of vaccines and biologicals under the premise of "biologicals for all".
Interests Represented
Promotes their own interests or the collective interests of their members
Member Of
WHO mRNA production consortium
Connected Legislation
Amendment: Annex II to Regulation (EU) 2019/6
Regulation on the criteria for the designation of antimicrobials to be reserved for the treatment of certain infections in humans
Correction: Delegated Regulation (EU) 2021/577 (Veterinary medicinal products)
Supplementing Regulation (EU) 2019/6: Single lifetime identification document
Regulation on the volume of sales and on the use of antimicrobial medicinal products in animals
Veterinary medicinal products
Regulation on appropriate measures to ensure the effective and safe use of veterinary medicinal products authorised and prescribed for oral administration via routes other than medicated feed and administered by the animal keeper to food-producing animals
Prohibition of certain antimicrobial products in animal imports
Amendment to Regulation (EU) 2019/6 on compliance with good laboratory practice for veterinary medicinal products set out in Annex II to that Regulation